Register Login

Aldeyra Therapeutics Inc. (ALDX)

(10% Negative) ALDEYRA THERAPEUTICS, INC. (ALDX) Announces Delay in modulator Trials for proof-of-concept clinical testing Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot Oct. 28, 2025, 11:02 a.m.

    📋 ALDEYRA THERAPEUTICS, INC. (ALDX) - Clinical Trial Update

    Filing Date: 2025-10-28

    Accepted: 2025-10-28 07:00:28

    Event Type: Clinical Trial Update

    Event Details:

    Aldeyra Therapeutics Inc. (ALDX) Announces Clinical Trial Update Aldeyra Therapeutics Inc. (ALDX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: modulator, improvement
    • Diseases/Conditions: proof-of-concept clinical testing, one month in a single-arm
    • Clinical Stage: Phase 2, Clinical Trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Phase 2 Clinical Trial
    • Updated Timeline: October 28, 2025

    🔬 Clinical Development Pipeline (ALDEYRA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Vehicle ophthalmic solution DRUG Phase PHASE3 Dry Eye Disease ClinicalTrials.gov
    Reproxalap ophthalmic solution (0.25%) DRUG Phase PHASE3 Dry Eye Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aldeyra Therapeutics Inc.
    • CIK: 0001341235
    • Ticker Symbol: ALDX
    • Period End Date: 2025-10-28
    • Document Type: 8-K

Search

News categories